Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 1, 2013, Pages 61-65

  Asmar, R ^a   Beebe Dimmer, J L ^b,c   Korgavkar, K ^a   Keele, G R ^b,c   Cooney, K A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BMI; diabetes; hypertension; insulin resistance; obesity

Indexed keywords

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CLINICAL FEATURE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; ONSET AGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RECURRENT CANCER; RISK ASSESSMENT; BLOOD; CANCER GRADING; CANCER STAGING; METABOLIC SYNDROME X; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR; TUMOR RECURRENCE;

PROSTATE SPECIFIC ANTIGEN;

DIABETES MELLITUS; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OBESITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84873736186     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.32     Document Type: Article

References (45)

1. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-131. (Pubitemid 23117853)
2. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011; 34: 216-219.
3. Day C. Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res 2007; 4: 32-38. (Pubitemid 46649071)
4. Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497. (Pubitemid 32433843)
5. Akintunde AA, Ayodele OE, Akinwusi PO, Opadijo GO. Metabolic syndrome: comparison of occurrence using three definitions in hypertensive patients. Clinl Med Res 2011; 9: 26-31.
6. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650. (Pubitemid 39331887)
7. Lund HL, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-774. (Pubitemid 44522081)
8. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007; 109: 875-881. (Pubitemid 46333529)
9. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A et al. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011; 71: 1492-1498.
10. Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 302-307. (Pubitemid 46383350)
11. Post JM, Beebe-Dimmer JL, Morgenstern H, Neslund-Dudas C, Bock CH, Nock N et al. The metabolic syndrome and biochemical recurrence following radical prostatectomy. Prostate Cancer 2012; 2011: 245642.
12. Bray GA. The underlying basis for obesity: relationship to cancer. J Nutr 2002; 132: 3451s-3455s. (Pubitemid 35315819)
13. Freedland SJ, Aronson WJ, Kane CJ, Presti Jr JC, Amling CL, Elashoff D et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004; 22: 446-453. (Pubitemid 41079773)
14. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007; 29: 88-97. (Pubitemid 47229642)
15. Montgomery JS, Gayed BA, Hollenbeck BK, Daignault S, Sanda MG, Montie JE et al. Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy. J Urol 2006; 176: 257-261.
16. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152: 1358-1368. (Pubitemid 24326262)
17. Cronin AM, Godoy G, Vickers AJ. Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. J Urol 2010; 183: 984-989.
18. Hanauer DA. EMERSE: The Electronic Medical Record Search Engine. American Medical Informatics Association Annual Symposium Proceedings 2006, 1189.
19. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
20. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH et al. Over-diagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-990. (Pubitemid 34814727)
21. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984. (Pubitemid 40638368)
22. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597. (Pubitemid 29211767)
23. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007; 51: 1175-1184. (Pubitemid 46436320)
24. Hsing AW, Sakoda LC, Chua S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86: s843-s857.
25. Freedland SJ, Terris MK, Presti Jr JC, Amling CL, Kane CJ, Trock B et al. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol 2004; 172: 520-524. (Pubitemid 38900194)
26. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 63-69. (Pubitemid 46174265)
27. Okasha M, McCarron P, McEwen J, Smith GD. Body mass index in young adulthood and cancer mortality: a retrospective cohort study. J Epidemiol Community Health 2002; 56: 780-784.
28. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638. (Pubitemid 36459468)
29. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-684. (Pubitemid 46233228)
30. Beebe-Dimmer JL, Faerber GJ, Morgenstern H, Werny D, Wojno K, Halstead-Nussloch B et al. Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study. Urology 2008; 71: 554-560.
31. Friedman GD. Blood pressure and heart rate: no evidence for a positive association with prostate cancer. Ann Epidemiol 1997; 7: 486-489.
32. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 2001; 11: 534-542. (Pubitemid 33049887)
33. Hammarsten J, Högstedt B. Clinical haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004; 13: 47-55. (Pubitemid 38455847)
34. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 1071-1078. (Pubitemid 38918167)
35. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 147-152. (Pubitemid 40096789)
36. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001; 10: 421-427. (Pubitemid 32701626)
37. Kaaks R, Lukanova A, Rinaldi S, Biessy C, Söderberg S, Olsson T. Interrelationships between plasma testosterone, SHBG, IGF-1, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003; 12: 309-315. (Pubitemid 36994086)
38. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: S6-S11.
39. Marchesi C, Ebrahimian T, Angulo O, Paradis P, Schiffrin EL. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension 2009; 54: 1384-1392.
40. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44: 248-252. (Pubitemid 39167216)
41. Saglam K, Aydur E, Yilmaz M, Göktaş S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003; 169: 1308-1311. (Pubitemid 36323773)
42. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801. (Pubitemid 44033299)
43. Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among U.S. adults:findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359. (Pubitemid 34251969)
44. Klabunde CN, Reeve BB, Harlan LC, Davis WW, Potosky AL. Do patients consistently report comorbid conditions over time?: results from the prostate cancer outcomes study. Med Care 2005; 43: 391-400. (Pubitemid 40515628)
45. Smith SC, Clark LT, Cooper RS, Daniels SR, Kumanyika SK, Ofili E et al. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. Circulation 2005; 111: e134-e139.